Table 2. Patient characteristics at end of 1L treatment by 2L therapy received.

	Any 2L treatment		No 2L treatment		Fluoro-pyrimidine-containing		Fluoro-pyrimidine combo		FOLFIRINOX		FOLFOX/OFF		Fluoro-pyrimidine mono		Other (than fluoro-pyrimidine-containing)a
	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem
n	170	177	250	226	132	135	98	107	18	17	36	49	34	28	38	42
Age, median, years	61.8	62.5	63.6	65.2	60.4	62.5	59.8	62.5	54.4	56.2	59.5	64.7	62.5	61.3	65.9	62.2
KPS
n	170	176	238	219	132	135	98	107	18	17	36	49	34	28	38	41
90–100, %	43	48	26	22	43	45	47	48	50	59	44	35	32	36	42	56
80, %	37	34	28	31	38	35	38	35	39	12	31	51	38	36	34	32
70, %	11	10	19	19	8	12	6	11	6	29	6	10	15	14	21	5
⩽60, %	9	8	27	28	11	8	9	7	6	0	19	4	15	14	3	7
CA19-9
n	144	131	168	120	112	99	84	76	16	10	32	33	28	23	32	32
U ml−1, median	276	380	246	1674	276	514	241	547	195	401	398	261	289	148	277	302
⩾59 × ULN, %	26	32	29	45	28	33	27	33	19	20	28	30	29	35	19	28
NLR ⩽5, %	74	67	59	44	77	64	77	65	72	71	69	63	79	61	61	76

Abbreviations: 1L=first-line; 2L=second-line; CA19-9=carbohydrate antigen 19-9; FOLFIRINOX=folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; FOLFOX=folinic acid, 5-fluorouracil, and oxaliplatin; Gem=gemcitabine; KPS=Karnofsky performance status; nab-P=nab-paclitaxel; NLR=neutrophil-to-lymphocyte ratio; OFF=oxaliplatin, folinic acid, and 5-fluorouracil; ULN=upper limit of normal.

^aRegimens in the Other category included the following: nab-P+Gem (for the 1L Gem arm only), nab-P monotherapy (for the 1L Gem arm only), erlotinib-containing regimens, and other Gem-based combinations.